AVALON-CAPITAL-PARTNERS
Avalon Capital Partners Limited (“Avalon”) has hired five senior cash equity salespeople as it continues with rapid expansion plans across both Event Driven and International Equities.
In the Event Driven division, Aaron Sawyer, Holger Klees and Gregory Lafitte have joined the team to bolster Avalon’s already considerable presence in this market.
In the International Equities Division, Conor Smith and Gavin Atkins join from Cantor Fitzgerald to lead the build out of an institutional cash equity desk, providing liquidity to an international client base.
“The continued expansion of Avalon with these hires is demonstration of our commitment to the Equity space. Where others are pulling out of equities, we are expanding. There is increasing investment in European equity and we have sales, research and trading teams ready to assist our clients in maximizing their returns,” said Jean-Yves Aknin, Avalon’s CEO.
“We are delighted to add Aaron, Holger, Gregory, Conor and Gavin to Avalon. Their track record and commitment to offering the best service to institutional customers is impressive and we look forward to their contribution to our success,” added Simon Langford, Avalon’s Managing Director.
Aaron Sawyer has over 20 years’ industry experience with resultant deep-seated market and multiple economic cycle expertise. Aaron has a strong background in Equity Finance, Special Situations, ECM and Long/Short alpha strategies. Before joining Avalon, Aaron spent ten years at Credit Suisse before joining Jefferies and then Macquarie to team-up with Holger on the build out of their European operations.
Holger Klees is a specialist in Event Driven with over 20 years’ experience. Prior to joining Avalon, Holger worked for Macquarie Bank and was part of Jefferies International’s European build out. He previously worked for Pali Capital and Lehman Brothers. Holger started his career in Derivatives Sales at BHF Bank where he set up a German focused arbitrage desk.
Gregory Lafitte brings sixteen years of expertise as a portfolio manager. He has covered a variety of markets but has a focus on US and Asian special situations. Gregory started his career at CM-CIC Market where he set up and developed the Asian merger arbitrage proprietary desk. He later relocated to Europe, joining Bred Banque Populaire in 2011, where he oversaw both the US and Asian merger arbitrage proprietary trading. Since then, Gregory has held roles Opera Trading and Makor Group.
Conor Smith brings 20 years of International Equities experience with extensive knowledge of equity analysis, market making, proprietary trading and sales. He has held roles at HSBC, Man Group, MF Global and Cantor Fitzgerald.
Gavin Atkins is an industry veteran who has spent 22 years in International Equities at Cantor Fitzgerald. Prior to that, Gavin held roles at Bishop Fleming and UBS.
About Avalon Capital Partners
One of the fastest growing brokerage firms in London, Avalon is an institutional broker providing extensive market knowledge and a dedication for providing a first-class service to a global institutional client base. At Avalon, client needs are our primary focus. We guarantee an unparalleled customer service from our dedicated and experienced teams, providing access to global markets and state-of-the-art technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005233/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
